miR-29 can ameliorate renal fibrosis (Ramdas et al., 2013; Solé et al., 2015) and HS (Guo et al., 2017) by targeting the canonical TGF-β signaling-related disintegrin metalloprotease Adams but inhibit liver fibrosis (Wang et al., 2015) by regulating the non-canonical TGF-β/PI3K/AKT signaling pathway. This evidence concerns the gene TGFB1 and renal fibrosis.